Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Ansbert Gadicke, insider at Cullinan Oncology
Ansbert Gadicke Insider Alerts

Get notified the next time Ansbert Gadicke buys or sells Cullinan Oncology stock. Enter your email address below to get our daily insider buying and selling report.

Ansbert Gadicke Insider Information

Director of Cullinan Oncology
Ansbert Gadicke is on the Board of Directors at Cullinan and a co-founder and Managing Director of MPM Capital and its venture capital activities as well as an investment committee member of its oncology-only crossover investment strategy (both public and private equities).

Ansbert co-founded MPM in 1997 with his partner Luke Evnin and was the lead investor and has served on the boards of several of MPM’s most successful investments including BioMarin, Idenix, Mitobridge, Pharmasset, and Radius. Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and previously, he was at The Boston Consulting Group.

Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert and Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. He is a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.

Ansbert received an MD from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at MIT and the Biochemistry Department at Harvard University. While at the German Cancer Research Center he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.

Ansbert currently serves as Chairman of the Board at TCR2 Therapeutics and as a Board Director at ElevateBio and iTeos Therapeutics.

What is Ansbert Gadicke's net worth?

The estimated net worth of Ansbert Gadicke is at least $4.02 million as of September 13th, 2021. Dr. Gadicke owns 248,170 shares of Cullinan Oncology stock worth more than $4,022,836 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Gadicke may own. Learn More.

How do I contact Ansbert Gadicke?

The corporate mailing address for Dr. Gadicke and other Cullinan Oncology executives is , , . Cullinan Oncology can also be reached via email at [email protected]

Has Ansbert Gadicke been buying or selling shares of Cullinan Oncology?

Ansbert Gadicke has not been actively trading shares of Cullinan Oncology within the last three months. Most recently, Ansbert Gadicke sold 888 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $29.16, for a transaction totalling $25,894.08.

Who are Cullinan Oncology's active insiders?

Cullinan Oncology's insider roster includes Ansbert Gadicke (Director), Jennifer Michaelson (Insider), Jeffrey Trigilio (CFO), and Leigh Zawel (Insider).

Are insiders buying or selling shares of Cullinan Oncology?

During the last twelve months, insiders at the sold shares 29 times. They sold a total of 278,563 shares worth more than $7,901,397.44. The most recent insider tranaction occured on October, 18th when insider Jennifer Michaelson sold 4,000 shares worth more than $85,680.00. Insiders at Cullinan Oncology own 21.8 % of the company.

Information on this page was last updated on 10/18/2021.

Ansbert Gadicke Insider Trading History at Cullinan Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2021Sell888$29.16$25,894.08View SEC Filing Icon  
9/13/2021Sell497$29.10$14,462.70248,170View SEC Filing Icon  
9/9/2021Sell1,898$29.35$55,706.30View SEC Filing Icon  
9/7/2021Sell3,465$29.04$100,623.60255,032View SEC Filing Icon  
9/3/2021Sell1,760$29.60$52,096.00255,032View SEC Filing Icon  
9/1/2021Sell790$29.47$23,281.30259,975View SEC Filing Icon  
8/30/2021Sell4,285$29.30$125,550.50264,437View SEC Filing Icon  
8/27/2021Sell1,846$29.09$53,700.14264,437View SEC Filing Icon  
8/25/2021Sell237$29.09$6,894.33View SEC Filing Icon  
8/23/2021Sell7,376$29.11$214,715.36View SEC Filing Icon  
8/11/2021Sell347$29.05$10,080.35280,921View SEC Filing Icon  
See Full Table

Ansbert Gadicke Buying and Selling Activity at Cullinan Oncology

This chart shows Ansbert Gadicke's buying and selling at Cullinan Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cullinan Oncology Company Overview

Cullinan Oncology logo
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $16.21
Low: $15.97
High: $17.37

50 Day Range

MA: $21.57
Low: $16.21
High: $25.00

2 Week Range

Now: $16.21
Low: $15.97
High: $59.85


167,330 shs

Average Volume

157,210 shs

Market Capitalization

$708.21 million

P/E Ratio


Dividend Yield



Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!